Fluconazole is a triazole antifungal indicated for vaginal, oropharyngeal and esophageal candidiasis and cryptococcal meningitis. We supply it to US manufacturers of tablets, oral suspension and injection.
Data from PubChem (CID 3365) and FDA’s substance registry
CAS number
86386-73-4
Molecular formula
C13H12F2N6O
Molecular weight
306.3g/mol
FDA UNII
IUPAC name
2-(2,4-difluorophenyl)-1,3-bis(1,2,4-triazol-1-yl)propan-2-ol
InChIKey
RFHAOTPXVQNOHP-UHFFFAOYSA-N
- Appearance
- White or almost white crystalline powder.
- Solubility
- Slightly soluble in water. Freely soluble in methanol, soluble in alcohol and acetone, and sparingly soluble in isopropanol.
Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.
Worth settling with your inquiry
Has more than one polymorph. State the form, and whether you need oral or injection grade.
On the US market
- Reference product
- DiflucanNDA 019949
- Approved ANDAs
- 19 with a marketed product
- Approved forms and strengths
- Tablet 50 mg, 100 mg, 150 mg, 200 mg
- Injection 100 mg/50 mL, 200 mg/100 mL, 400 mg/200 mL
- Powder for oral suspension 50 mg/5 mL, 200 mg/5 mL
Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.
Grade
USP or Ph. Eur. where a monograph exists, or your own specification.
Quantities
From development quantities for formulation work to commercial supply.
Packaging
To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.
Regulatory filings
US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.
Documents available with a quote
- Specification and certificate of analysis
- Safety data sheet
- Method of analysis
- DMF letter of authorization, where a US DMF is filed
- GMP certificate and inspection history of the site
- Residual solvents and elemental impurities statements
- Nitrosamine risk assessment
- TSE/BSE statement
Need something else for your QA file? Email info@yogpharma.com